Skip to main content

DM1

1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Avidity Biosciences
Avidity BiosciencesCA - San Diego
1 program
1
AOC 1001Phase 1/22 trials
Active Trials
NCT07008469Enrolling By Invitation230Est. Oct 2030
NCT05027269Completed39Est. Feb 2023
Vertex Pharmaceuticals
1 program
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) ExtensionN/A
Dyne Therapeutics
1 program
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) ExtensionN/A1 trial
Active Trials
NCT07700225Recruiting1,000Est. Dec 2032

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Avidity BiosciencesAOC 1001
Avidity BiosciencesAOC 1001
Dyne TherapeuticsEstablishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Clinical Trials (3)

Total enrollment: 1,269 patients across 3 trials

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

Start: Jun 2025Est. completion: Oct 2030230 patients
Phase 3Enrolling By Invitation

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Start: Oct 2021Est. completion: Feb 202339 patients
Phase 1/2Completed
NCT07700225Dyne TherapeuticsEstablishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Start: Jul 2026Est. completion: Dec 20321,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,269 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.